JP2013530160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530160A5 JP2013530160A5 JP2013512611A JP2013512611A JP2013530160A5 JP 2013530160 A5 JP2013530160 A5 JP 2013530160A5 JP 2013512611 A JP2013512611 A JP 2013512611A JP 2013512611 A JP2013512611 A JP 2013512611A JP 2013530160 A5 JP2013530160 A5 JP 2013530160A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- composition according
- modification
- antisense oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims 6
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 208000008601 Polycythemia Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29678310P | 2010-01-20 | 2010-01-20 | |
| US61/296,783 | 2010-01-20 | ||
| US28254610P | 2010-02-26 | 2010-02-26 | |
| US61/282,546 | 2010-02-26 | ||
| PCT/US2011/021886 WO2012148373A1 (en) | 2010-01-20 | 2011-01-20 | Antimir-451 for the treatment of polycythemias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013530160A JP2013530160A (ja) | 2013-07-25 |
| JP2013530160A5 true JP2013530160A5 (enExample) | 2014-03-06 |
Family
ID=47072618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512611A Pending JP2013530160A (ja) | 2010-01-20 | 2011-01-20 | 赤血球増加症治療用ａｎｔｉｍｉＲ−４５１ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9340782B2 (enExample) |
| EP (1) | EP2536436A4 (enExample) |
| JP (1) | JP2013530160A (enExample) |
| CN (1) | CN102869386A (enExample) |
| WO (1) | WO2012148373A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970968B1 (en) | 2013-03-15 | 2018-01-10 | Miragen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| WO2016094406A1 (en) * | 2014-12-08 | 2016-06-16 | Thomas Jefferson University | Treatment and prevention of thrombosis using an anti-mir |
| US10306081B2 (en) * | 2015-07-09 | 2019-05-28 | Turner Broadcasting System, Inc. | Technologies for generating a point-of-view video |
| ES2659845B1 (es) | 2016-09-19 | 2019-01-04 | Univ Valencia | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
| CN113332434B (zh) * | 2021-05-25 | 2023-09-05 | 大连医科大学 | miR-451a调节剂在制备调控血压制剂中的应用 |
| EP4506010A1 (en) | 2022-04-06 | 2025-02-12 | Universitat de València | Antagonists of human micro rna mir-100, mir-20, mir-222, mir-181 and mir-92 and uses of same |
| CN115920054A (zh) * | 2022-12-23 | 2023-04-07 | 扬州大学 | miR-144/451作为靶点在治疗精神分裂症中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1883709A4 (en) | 2005-04-29 | 2010-10-13 | Univ Rockefeller | HUMAN MICRO-RNAS AND METHOD OF INHIBITING THEM |
| KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
| EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
| CA2726052A1 (en) * | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
-
2011
- 2011-01-20 EP EP11856627.2A patent/EP2536436A4/en not_active Withdrawn
- 2011-01-20 JP JP2013512611A patent/JP2013530160A/ja active Pending
- 2011-01-20 WO PCT/US2011/021886 patent/WO2012148373A1/en not_active Ceased
- 2011-01-20 US US13/574,398 patent/US9340782B2/en not_active Expired - Fee Related
- 2011-01-20 CN CN2011800142685A patent/CN102869386A/zh active Pending